{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:33:28Z","timestamp":1771382008401,"version":"3.50.1"},"reference-count":13,"publisher":"Walter de Gruyter GmbH","issue":"2","funder":[{"name":"Intramural Funding, JIPMER","award":["JIP\/DEAN(R)\/INTRAMURAL\/PHS 1\/2019-20 [Dt 10\/9\/2019]"],"award-info":[{"award-number":["JIP\/DEAN(R)\/INTRAMURAL\/PHS 1\/2019-20 [Dt 10\/9\/2019]"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,5]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n \n Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having a\u00a0role in the requirement of CBZ maintenance dose. The aim was to study the influence of\n EPHX1<\/jats:italic>\n c.337\u00a0T>C and\n UGT2B7*2<\/jats:italic>\n genetic polymorphisms on CBZ maintenance dose requirement in persons with epilepsy.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Persons with epilepsy (PWE) of both gender of age 15\u201365 years on carbamazepine monotherapy who had been taking same maintenance dose for one year were eligible. Five milliliter of venous blood was collected in 10%\u00a0EDTA under aseptic precautions. After centrifugation, the cellular component was used for DNA extraction and genotyping. For three genotypes of\n EPHX1<\/jats:italic>\n c.337\u00a0T>C and\n UGT2B7*2<\/jats:italic>\n , the differences in mean carbamazepine dose were analyzed using Analysis of Variance (ANOVA). An unpaired t-test was used to draw a comparison between the\u00a0genotypes and CBZ maintenance dose requirement for\u00a0dominant and recessive models of\n EPHX1 c.337\u00a0T>C<\/jats:italic>\n and\u00a0\n UGT2B7*2<\/jats:italic>\n . A value of p<0.05 was considered to be statistically significant.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n For\n UGT2B7*2<\/jats:italic>\n (rs 7439366), CT required a higher dose (CT 626\u00a0mg\/day and TT 523\u00a0mg\/day) but not found to\u00a0be\u00a0significant (p-value 0.167). PWE carrying CT genotype\u00a0of\u00a0\n EPHX1<\/jats:italic>\n c.337\u00a0T>C had 62\u00a0mg higher dose when compared to homozygous mutant CC (590\u00a0mg\/day for CT and 528\u00a0mg\/day for CC) but p-value was not found to be significant (p-value 0.835).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The results of our study done in 115 PWE showed there was a lack of association between SNPs of\n EPHX1<\/jats:italic>\n c.337\u00a0T>C,\n UGT2B7*2<\/jats:italic>\n and CBZ maintenance dose requirement in Southern part of India and this finding has to\u00a0be confirmed in a larger sample size.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/dmpt-2022-0157","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T12:54:56Z","timestamp":1677588896000},"page":"191-197","source":"Crossref","is-referenced-by-count":4,"title":["Influence of\n EPHX1<\/i>\n c.337\u00a0T>C and\n UGT2B7*2<\/i>\n genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-7960","authenticated-orcid":false,"given":"Shravan","family":"Venkatraman","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology , JIPMER , Puducherry , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesavan","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep P.","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Neurology , Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadharsini","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"2025121207125700573_j_dmpt-2022-0157_ref_001","doi-asserted-by":"crossref","unstructured":"Johnson, EL. Seizures and epilepsy. Med Clin 2019;103:309\u201324. https:\/\/doi.org\/10.1016\/j.mcna.2018.10.002.","DOI":"10.1016\/j.mcna.2018.10.002"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_002","doi-asserted-by":"crossref","unstructured":"McMillin, GA, Juenke, JM, Tso, G, Dasgupta, A. Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays. Am J Clin Pathol 2010;133:728\u201336. https:\/\/doi.org\/10.1309\/ajcpfahvb26vvvte.","DOI":"10.1309\/AJCPFAHVB26VVVTE"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_003","doi-asserted-by":"crossref","unstructured":"Oh, E, Ban, E, Woo, JS, Kim, CK. Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography. Anal Bioanal Chem 2006;386:1931\u20136. https:\/\/doi.org\/10.1007\/s00216-006-0724-7.","DOI":"10.1007\/s00216-006-0724-7"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_004","doi-asserted-by":"crossref","unstructured":"Puranik, YG, Birnbaum, AK, Marino, SE, Ahmed, G, Cloyd, JC, Remmel, RP, et al.. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 2013;14:35\u201345. https:\/\/doi.org\/10.2217\/pgs.12.180.","DOI":"10.2217\/pgs.12.180"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_005","doi-asserted-by":"crossref","unstructured":"Hung, CC, Chang, WL, Ho, JL, Tai, JJ, Hsieh, TJ, Huang, HC, et al.. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 2012;13:159\u201369. https:\/\/doi.org\/10.2217\/pgs.11.141.","DOI":"10.2217\/pgs.11.141"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_006","doi-asserted-by":"crossref","unstructured":"Staines, AG, Coughtrie, MW, Burchell, B. N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Therapeut 2004;311:1131\u20137. https:\/\/doi.org\/10.1124\/jpet.104.073114.","DOI":"10.1124\/jpet.104.073114"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_007","doi-asserted-by":"crossref","unstructured":"Lu, Q, Huang, YT, Shu, Y, Xu, P, Xiang, DX, Qu, Q, et al.. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients. Medicine (Baltim) 2018;97:e11662. https:\/\/doi.org\/10.1097\/md.0000000000011662.","DOI":"10.1097\/MD.0000000000011662"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_008","doi-asserted-by":"crossref","unstructured":"Reich, D, Thangaraj, K, Patterson, N, Price, AL, Singh, L. Reconstructing Indian population history. Nature 2009;461:489\u201394. https:\/\/doi.org\/10.1038\/nature08365.","DOI":"10.1038\/nature08365"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_009","unstructured":"Census (2011), Primary Census Abstracts, Registrar General of India, MInistry of Home Affairs, Government of India."},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_010","doi-asserted-by":"crossref","unstructured":"Ma, CL, Jiao, Z, Wu, XY, Hong, Z, Wu, ZY, Zhong, MK. Association between PK\/PD-involved gene polymorphisms and carbamazepine-individualized therapy. Pharmacogenomics 2015;16:1499\u2013512. https:\/\/doi.org\/10.2217\/pgs.15.94.","DOI":"10.2217\/pgs.15.94"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_011","doi-asserted-by":"crossref","unstructured":"Zhu, X, Yun, W, Sun, X, Qiu, F, Zhao, L, Guo, Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics 2014;15:1867\u201379. https:\/\/doi.org\/10.2217\/pgs.14.142.","DOI":"10.2217\/pgs.14.142"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_012","doi-asserted-by":"crossref","unstructured":"Daci, A, Beretta, G, Vllasaliu, D, Shala, A, Govori, V, Norata, GD, et al.. Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. PLoS One 2015;10:e0142408. https:\/\/doi.org\/10.1371\/journal.pone.0142408.","DOI":"10.1371\/journal.pone.0142408"},{"key":"2025121207125700573_j_dmpt-2022-0157_ref_013","doi-asserted-by":"crossref","unstructured":"Ganesapandian, M, Ramasamy, K, Adithan, S, Narayan, SK. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients\u00a0in the South Indian population. Indian J Pharmacol 2019;51:384\u20138. https:\/\/doi.org\/10.4103\/ijp.IJP_122_19.","DOI":"10.4103\/ijp.IJP_122_19"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2022-0157\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2022-0157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:00:46Z","timestamp":1765526446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2022-0157\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,16]]},"published-print":{"date-parts":[[2023,6,5]]}},"alternative-id":["10.1515\/dmpt-2022-0157"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2022-0157","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}